Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report

Theleritis, Christos G.; Papadimitriou, George N.; Papageorgiou, Charalabos C.; Dikeos, Dimitris G.; Masdrakis, Vasilis; Kostoulas, Constantin; Psarros, Constantin; Soldatos, Constantin R.
January 2006
BMC Psychiatry;2006, Vol. 6, p37
Academic Journal
Background: The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation: A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg). Conclusion: The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient.


Related Articles

  • Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.

  • Orlistat: A Viewpoint by Madeleine L. Drent. Drent, M.L. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Physiological effects of orlistat; Effectiveness; Adverse effects.

  • Orlistat. McNeely, W.; Benfield, P. // Drugs;Aug1998, Vol. 56 Issue 2, p241 

    â–´ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. â–´ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in...

  • Orlistat.  // Reactions Weekly;9/17/2011, Issue 1369, p30 

    The article describes the case of a woman who developed a lichenoid drug eruption (LDE) following treatment with orlistat for obesity.

  • Market impact remains unclear as pending switches head to stores. Johnsen, Michael // Drug Store News;1/17/2005, Vol. 27 Issue 1, p34 

    Reports on the increasing category sales among blockbuster drug switches in the U.S. Introduction of a new nonprescription alternative for the diet aid set in 2006; Amendment of switch application for the emergency contraceptive plan B; Plan of GlaxoSmithKline to file a switch application for...

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • Press coverage and sales of Xenical in Sweden, 1998—2000. Brounéus, Fredrik; Dahlin, Anna; Beermann, Björn // European Journal of Clinical Pharmacology;Jun2005, Vol. 61 Issue 4, p285 

    Objective: The anti-obesity drug Xenical (orlistat, Roche) was launched on the Swedish market in February 1999. The sales peaked in May 1999 and then declined. The purpose of this study was to investigate the press coverage of Xenical during the period 1998–2000 and, if possible, relate...

  • Supplier News.  // Drug Store News;5/2/2005, Vol. 27 Issue 6, p41 

    The article reports that GlaxoSmithKline PLC has agreed to promote Roche Inc.'s prescription weight-loss drug Xenical or orlistat to physicians in the U.S. just months before GlaxoSmithKline plans to file an application to switch orlistat to over-the-counter status with a different dosing...

  • Pharmacotherapy for obesity. Kyoung Kon Kim // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Apr2011, Vol. 54 Issue 4, p409 

    Due to its serious comorbidities and high prevalence, obesity is one of the heaviest burdens for public health. Although diet, exercise and behavioral modification are the first-line treatment for obesity, their outcomes are not satisfactory. The goal of this article is to review currently...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics